USCWA
KYNB

U.S. Capital Wealth Advisors’s Kyntra Bio KYNB Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-136
Closed -$54.4K – 939
2022
Q4 		$54.4K Buy
+136
New +$52.1K ﹤0.01% 859

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

U.S. Capital Wealth Advisors's KYNB Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Kyntra Bio (KYNB) in Q1 2023, closing a stake of 136 shares — an estimated $54.4K sold.

U.S. Capital Wealth Advisors first reported a position in KYNB in Q4 2022 and held it in 1 quarter. The position peaked at $54.4K in Q4 2022. 171 funds tracked by Wall St. Rank hold KYNB as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Kyntra Bio position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 136 Kyntra Bio shares in Q1 2023, an estimated $54.4K.
  • U.S. Capital Wealth Advisors first reported a position in Kyntra Bio in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Kyntra Bio position peaked at $54.4K in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.